PALO ALTO, Calif. – September 10, 2026 – Vivo Capital (“Vivo” or the “Firm”), a leading global healthcare investment firm, today announced the appointment of Mr. Neetesh Kumar as Managing Partner. Mr. Kumar will co-lead…
As Vivo Capital celebrates its 30th anniversary, we are launching a new philanthropic initiative that expands our commitment to advancing healthcare innovation globally and creating positive impact beyond investing.
Dear Friends of Vivo, As we approach the 30th anniversary of Vivo’s founding, we have been reflecting on the remarkable journey that brought us here.
A legacy defined by innovation, leadership, and humanity. We are extremely saddened to share that our Managing Partner, Jack B. Nielsen, passed away on June 5th, 2025, after a courageous year-long battle with cancer. Jack…
Palo Alto, May 7th, 2025: Vivo Capital (“Vivo” or “the Firm”), a leading global investment firm focused exclusively on healthcare and life sciences, has closed the third cycle of its Vivo Opportunity Fund and its…
PALO ALTO, Calif.–(BUSINESS WIRE)–Vivo Capital (“Vivo” or the “Firm”), a leading global investment firm focused exclusively on healthcare and life sciences, today announced multiple legal proceedings to challenge the irresponsible actions taken by the current…
In August 2023, Vivo Capital, as a co-lead investor, successfully completed the A-round financing settlement with Wuhan Createrna Science and Technology Co., Ltd. (hereinafter referred to as “Createrna”). After the settlement, the total amount raised…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the reach of innovative medicines in Greater China.